Literature DB >> 1589986

Locally recurrent rectal cancer: surgical strategy.

J P de Azevedo1, R R Dozois, L L Gunderson.   

Abstract

Relapses after "curative resection" of rectal cancer may be localized and thus amenable to surgical treatment. The risk of relapse may be higher than previously believed depending on adequacy and length of follow-up, the diagnostic modalities used, and the number of autopsies performed. Technical refinements such as a distal margin greater than 2 cm, radical pelvic lymphadenectomy, and high ligation of the inferior mesenteric artery at the aorta do not appear to diminish the risk of recurrence. A wider lateral margin and a more complete excision of the mesorectum may be beneficial, but this is yet unproven. Surgery for isolated, locally recurrent lesions should be limited to carefully selected patients and performed in tertiary centers using a team approach. Whether such radical "salvage" procedures are justifiable merits further careful evaluation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1589986     DOI: 10.1007/bf02104453

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  37 in total

Review 1.  Rectal cancer: current management.

Authors:  R R Dozois; R E Perry
Journal:  Curr Probl Surg       Date:  1990-05       Impact factor: 1.909

2.  Quantitative magnetic resonance imaging in rectal carcinoma.

Authors:  R J Johnson; J P Jenkins; I Isherwood; R D James; P F Schofield
Journal:  Br J Radiol       Date:  1987-08       Impact factor: 3.039

3.  Areas of failure found at reoperation (second or symptomatic look) following "curative surgery" for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy.

Authors:  L L Gunderson; H Sosin
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

4.  Influence of splenectomy on survival rate of patients with colorectal cancer.

Authors:  C J Davis; D M Ilstrup; J H Pemberton
Journal:  Am J Surg       Date:  1988-01       Impact factor: 2.565

5.  Indications for local excision of rectal cancer.

Authors:  M J Killingback
Journal:  Br J Surg       Date:  1985-09       Impact factor: 6.939

6.  Importance of tumor morphology for the long term prognosis of rectal adenocarcinoma.

Authors:  F Michelassi; L Vannucci; A Montag; R Goldberg; R Chappell; H Dytch; M Bibbo; G E Block
Journal:  Am Surg       Date:  1988-06       Impact factor: 0.688

7.  The relative prognostic value of flow cytometric DNA analysis and conventional clinicopathologic criteria in patients with operable rectal carcinoma.

Authors:  N A Scott; L M Rainwater; H S Wieand; L H Weiland; J H Pemberton; R W Beart; M M Lieber
Journal:  Dis Colon Rectum       Date:  1987-07       Impact factor: 4.585

8.  Computed tomographic scanning in rectal carcinoma.

Authors:  G Zheng; R J Johnson; B Eddleston; R D James; P F Schofield
Journal:  J R Soc Med       Date:  1984-11       Impact factor: 5.344

9.  Blood transfusion and recurrence of cancer of the colon and rectum.

Authors:  D M Francis; R T Judson
Journal:  Br J Surg       Date:  1987-01       Impact factor: 6.939

10.  Pelvic recurrence of rectal cancer. Options for curative resection.

Authors:  H J Wanebo; D L Gaker; R Whitehill; R F Morgan; W C Constable
Journal:  Ann Surg       Date:  1987-05       Impact factor: 12.969

View more
  2 in total

1.  Incidence and survival of patients with Dukes' A (stages T1 and T2) colorectal carcinoma: a 15-year population-based study.

Authors:  Carmela Di Gregorio; Piero Benatti; Lorena Losi; Luca Roncucci; Giuseppina Rossi; Giovanni Ponti; Massimiliano Marino; Monica Pedroni; Alessandra Scarselli; Barbara Roncari; Maurizio Ponz de Leon
Journal:  Int J Colorectal Dis       Date:  2004-12-09       Impact factor: 2.571

2.  Impact of multimodal therapy in locally recurrent rectal cancer.

Authors:  Y N You; J M Skibber; C-Y Hu; C H Crane; P Das; E S Kopetz; C Eng; B W Feig; M A Rodriguez-Bigas; G J Chang
Journal:  Br J Surg       Date:  2016-03-02       Impact factor: 6.939

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.